Conteltinib (Synonyms: CT-707) |
| Katalog-Nr.GC35728 |
Conteltinib (CT-707) ist ein Multi-Kinase-Inhibitor, der auf FAK, ALK und Pyk2 abzielt. Conteltinib Übt mit einem IC50 von 1,6 nM eine signifikante Hemmwirkung auf FAK aus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1384860-29-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib (CT-707) exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM[1]. IC50: 1.6 nM (FAK)[1]
[1]. Wang DD, et al. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation. Mol Cancer Ther. 2016 Dec;15(12):2916-2925.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *